TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) Market Cap & Valuation Ratios
TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) has a market cap of $45.9B and a price-to-sales ratio of 2.6, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
TEVATEVA PHARMACEUTICAL INDUSTRIES LTDFollow TEVA — free
—
Price chart with a free account
- Market cap
- 45.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Peers
drug manufacturers - general · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| TEVA | 46 | — | 3.4 | 22.7 | 2.9% | +4% | 9% | 7% |
| ABBV | 505 | 80.7 | 8.8 | 23.0 | 3.6% | +10% | 26% | 21% |
| MRK | 358 | 115.3 | 6.1 | 28.1 | 4.5% | +5% | 12% | 5% |
| AZN | 274 | 25.7 | 4.9 | 14.7 | 4.3% | +9% | 23% | 16% |
| AMGN | 237 | 27.3 | 7.4 | 17.4 | 4.3% | +9% | 30% | 18% |
| GILD | 193 | — | 7.1 | 823.4 | 6.7% | +6% | -8% | -7% |
| PFE | 171 | 39.5 | 3.5 | 16.8 | 6.4% | -0.2% | 11% | 4% |
| BMY | 126 | 13.5 | 3.2 | 9.4 | 9.1% | +3% | 28% | 19% |
| ONC | 43 | 67.6 | 6.5 | 36.9 | 3.1% | +34% | 15% | 35% |
| BIIB | 37 | 44.5 | 4.4 | 20.5 | 7.3% | +0.3% | 13% | 5% |
| BLTE | 5.8 | — | — | — | -0.6% | — | — | -20% |
| Median of these 10 | 42.0 | 6.1 | 20.5 | 4.4% | +6% | 15% | 11% |
; EV/Sales 3.4 vs. 6.1.
Growth vs. price
each dot a company · hover or tap for valuesTEVA and GILD and BLTE have no P/E (earnings not positive) and are left out · hover or tap a dot for values.
TEVA PHARMACEUTICAL INDUSTRIES LTD — questions
- What is TEVA PHARMACEUTICAL INDUSTRIES LTD's market cap?
- $45.9B.
- What is TEVA PHARMACEUTICAL INDUSTRIES LTD's price-to-sales ratio?
- 2.6.
Every figure on this page comes from TEVA PHARMACEUTICAL INDUSTRIES LTD's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.